Carrick Therapeutics UK Ltd. has synthesized cyclin-dependent kinase 12 (CDK12) and/or cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of autoimmune diseases, cardiovascular disorders, fragile X syndrome, muscular dystrophy, neurodegeneration, renal disorders and cancer.